公开(公告)号：US20150140099A1

公开(公告)日：2015-05-21

申请号：US14404199

申请日：2013-05-30

Applicant: ALMIRALL, S.A.

Inventor： Sandrine Allain Ruiz ,  Beatriz Seoane Nunez ,  Gonzalo De Miguel Serra

IPC: A61K31/4704 ,  A61K45/06 ,  A61K31/58 ,  A61K9/00

CPC classification number: A61K31/4704 ,  A61K9/0073 ,  A61K9/0075 ,  A61K31/58 ,  A61K45/06

Abstract: A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base.

Abstract translation: 一种用于吸入的药物组合物，其包含与药学上可接受的盐的干燥粉末形式的药物组合物，其与药学上可接受的干粉载体混合，提供相当于约322微克游离碱的递送剂量的吖啶鎓。

公开(公告)号：US20150118312A1

公开(公告)日：2015-04-30

申请号：US14403220

申请日：2013-05-24

Applicant: ALMIRALL S.A.

Inventor： Rosa Lamaraca Casado ,  Gonzalo De Miquel Serra

IPC: A61K9/00 ,  A61M15/00 ,  A61K45/06 ,  A61K31/167 ,  A61K31/439 ,  A61K47/26

CPC classification number: A61K31/439 ,  A61K9/0075 ,  A61K31/167 ,  A61K31/46 ,  A61K31/4706 ,  A61K31/573 ,  A61K45/06 ,  A61K47/26 ,  A61M11/00 ,  A61M15/00 ,  A61M15/0021 ,  A61M15/0038 ,  A61M15/0051 ,  A61M15/0086 ,  A61M2202/064 ,  F04C2270/0421 ,  A61K2300/00

Abstract: A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base.

Abstract translation: 一种用于吸入的药物组合物，其包含与药学上可接受的盐的干燥粉末形式的药物组合物，其与药学上可接受的干粉载体混合，提供相当于约322微克游离碱的递送剂量的吖啶鎓。

公开(公告)号：US20150118186A1

公开(公告)日：2015-04-30

申请号：US14589056

申请日：2015-01-05

Applicant: ALMIRALL, S.A.

Inventor： Jordi BACH TAÑA ,  Lluis Miquel PAGES SANTACANA ,  Joan TALTAVULL MOLL ,  Paul Robert EASTWOOD ,  Jacob GONZALEZ RODRIGUES ,  Victor GIULIO MATASSA

IPC: C07D487/04 ,  A61K31/506 ,  A61K45/06 ,  A61K31/4985 ,  A61K31/497 ,  C07D471/04 ,  A61K31/437

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/506 ,  A61K45/06 ,  C07D471/04

Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Abstract translation: 公开了具有式（I）化学结构的新的吡唑衍生物; 以及用于盗窃制备的方法，包含它们的药物组合物及其在治疗中作为Janus Kinases（JAK）抑制剂的用途。

公开(公告)号：US20140373838A1

公开(公告)日：2014-12-25

申请号：US14373572

申请日：2013-01-17

Applicant: Almirall, S.A.

Inventor： Martin Herder ,  Gerhard Ludanek ,  Ingo Mett ,  Joachim Schmidt

IPC: A61M15/00

Abstract: The invention relates to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient, said activating device being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when pressed by the patient. The inhalation device further comprises an advancing mechanism for advancing a counter means each time the inhalation device has been activated by the patient so that a powder dose has been released into the powder channel. The counter means comprises a mechanical index coupled to a locking mechanism blocking the dosage key (5) and/or the activating device and/or the transportation mechanism after a predetermined number of metering cycles after detection of the index. Moreover, the locking mechanism includes a locking lever (7) for positive engagement with the dosage key (5) and/or the activating device and/or the transportation mechanism in the blocked condition. The inhalation device (1) is characterized in that the locking lever includes signaling means integrally formed therewith engaging the index after said predetermined number of metering cycles.

Abstract translation: 本发明涉及一种由吸入引起的气流由患者接收的粉末药物的吸入装置，其包括至少一个粉末储存器，用于从贮存器反复计量粉末剂量的计量装置，用于移动所述计量 从填充位置的装置，用于将粉末剂量接收到用于将所述粉末剂量释放到粉末通道中的排空位置，用于由患者手动操作的至少一个致动装置，所述致动装置可操作地连接到所述运输机构，使得在操作 正在计量单一粉剂量，所述活化装置包括当由患者按压时作用在所述运输机构上的剂量密钥（5）。 吸入装置还包括一个推进机构，用于在每次吸入装置已被患者激活时推进计数器装置，从而将粉末剂量释放到粉末通道中。 计数器装置包括机械指标，其耦合到锁定机构，该锁定机构在检测到索引之后经过预定数量的计量循环之后阻止剂量密钥（5）和/或启动装置和/或运输机构。 此外，锁定机构包括用于与封闭状态下的剂量密钥（5）和/或启动装置和/或运输机构正接合的锁定杆（7）。 吸入装置（1）的特征在于，锁定杆包括在所述预定数量的计量循环之后与所述索引一体形成的信号装置。

公开(公告)号：US20140373837A1

公开(公告)日：2014-12-25

申请号：US14373568

申请日：2013-01-17

Applicant: Almirall, S.A.

Inventor： Martin Herder ,  Gerhard Ludanek ,  Ingo Mett ,  Joachim Schmidt

IPC: A61M15/00

Abstract: The invention refers to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when actuated by the patient. According to the invention, said transportation mechanism furthermore comprises a dosage lever (6) acting on said metering means, said dosage lever (6) being locked in the inhalation position of said metering means after said dosage key (5) has been properly pressed down by the patient. The dosage lever (6) in the inhalation position engages a trigger member and is releasable by actuation of the trigger member. The trigger member comprises at least one cam surface and the dosage lever (6) engages the cam surface tangentially in said locked inhalation position.

Abstract translation: 本发明涉及一种用于通过吸入引起的空气流由患者接受的粉末药物的吸入装置，其包括至少一个粉末储存器，用于从储存器反复计量粉末剂量的计量装置，用于移动所述计量 用于从用于将粉末剂量接收到排空位置以将所述粉末剂量释放到粉末通道中的填充位置的装置，用于由患者手动操作的至少一个激活装置，其可操作地连接到所述运输机构，使得在操作时单一粉末剂量 所述激活装置包括当由患者致动时作用在所述运送机构上的剂量密钥（5）。 根据本发明，所述运送机构还包括作用在所述计量装置上的剂量控制杆（6），所述剂量控制杆（6）在所述剂量键（5）被适当地按压之后被锁定在所述计量装置的吸入位置 由病人 吸入位置中的剂量杆（6）接合触发构件，并且通过触发构件的致动可释放。 所述触发器构件包括至少一个凸轮表面，并且所述剂量杆（6）在所述锁定的吸入位置中切向地接合所述凸轮表面。

公开(公告)号：US08802699B2

公开(公告)日：2014-08-12

申请号：US13939742

申请日：2013-07-11

Applicant: Almirall, S.A.

Inventor： Maria Dolors Fernandez Forner ,  Maria Prat Quinones ,  Maria Antonia Buil Albero

IPC: A61K31/439 ,  A61K31/56 ,  A61K45/06 ,  A61K31/4745 ,  C07D453/02

CPC classification number: A61K31/439 ,  A61K9/0073 ,  A61K9/0075 ,  A61K31/4745 ,  A61K31/56 ,  A61K45/06 ,  A61K47/26 ,  C07D453/02 ,  Y10S514/826 ,  A61K2300/00

Abstract: Provided is a pharmaceutical composition comprising: (i) 3-(2-hydroxy-2,2-dithien-2- ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo-[2.2.2]octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X−with a single negative charge is associated with the positive charge of the nitrogen atom; and (ii) a phosphodiesterase IV inhibitor and methods of using the same.

Abstract translation: 本发明提供的药物组合物包含：（i）3-（2-羟基-2,2-二噻吩-2-基乙酰氧基）-1-（3-苯氧基丙基）-1-氮鎓二环[2.2.2]辛烷或对映异构体， 对映异构体或其外消旋体的混合物，其中具有单个负电荷的阴离子X与氮原子的正电荷相关联; 和（ii）磷酸二酯酶IV抑制剂及其使用方法。

公开(公告)号：US20140005178A1

公开(公告)日：2014-01-02

申请号：US13964181

申请日：2013-08-12

Applicant: Almirall, S.A.

Inventor： Julio Cesar CASTRO PALOMINO LARIA ,  Emma Terricabras Belart ,  Montserrat Erra Sola ,  Eloisa Navarro Romero ,  Siliva Fonquerna Pou ,  Aranzazu Cardus Figueras ,  Maria Estrella Lozoya Toribio

IPC: C07D213/74 ,  A61K31/5377 ,  A61K31/505 ,  A61K31/47 ,  C07D413/10 ,  A61K31/444 ,  A61K31/44 ,  C07D239/42 ,  C07D215/38 ,  A61K45/06 ,  A61K31/55 ,  A61K31/4545

CPC classification number: C07D213/74 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D215/38 ,  C07D239/42 ,  C07D401/04 ,  C07D401/10 ,  C07D413/10

Abstract: The present disclosure relates to new azabiphenylaminobenzoic acid derivatives of formula (I); as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH).

Abstract translation: 本公开涉及式（I）的新的氮杂二苯胺基苯甲酸衍生物; 以及它们的制备方法，包含它们的药物组合物及其在治疗中作为脱氢山梨醇二氢化酶（DHODH）抑制剂的用途。

公开(公告)号：US20230235040A1

公开(公告)日：2023-07-27

申请号：US18002882

申请日：2021-06-21

Applicant: Almirall, S.A.

Inventor： Thomas Huber ,  Vicente Marco Garcia Gonzalez ,  Bernat Vidal Juan ,  Germaine Fuh-Kelly ,  Yao-ming Huang

IPC: C07K16/24

CPC classification number: C07K16/244 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2317/76

Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36α, IL-36β, and/or IL-36γ, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.

公开(公告)号：US20210220328A1

公开(公告)日：2021-07-22

申请号：US16768940

申请日：2018-12-07

Applicant: Almirall, S.A.

Inventor： Jordi BACH TAÑA ,  Cristina ESTEVE TRIAS ,  Marta MIR CEPEDA

IPC: A61K31/40 ,  C07D207/34 ,  A61K31/4025 ,  C07D405/06 ,  A61K31/573 ,  A61K31/593 ,  A61K31/203 ,  A61K39/395 ,  A61K38/17 ,  A61K31/20

Abstract: Novel pyrrole derivatives of Formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Acetyl-CoA carboxylase (ACC).

公开(公告)号：US10759793B2

公开(公告)日：2020-09-01

申请号：US15735235

申请日：2016-06-10

Applicant: ALMIRALL, S.A.

Inventor： Cristina Esteve Trias ,  Joan Taltavull Moll ,  Jacob Gonzalez Rodriguez ,  Bernat Vidal Juan

IPC: C07D471/04 ,  C07D239/24

Abstract: New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of Janus Kinases (JAK).